amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of General Medical Sciences Special Emphasis Panel (SEP) meeting:

Committee Name: Minority Access to Research Careers (MARC) and Minority Biomedical Research Support (MBRS) Special Emphasis Panel.

Date: November 20, 1996.

Time: 12:30 p.m.—adjournment.

Place: National Institutes of Health (Telephone Conference), 45 Center Drive, Room 1AS–13F, Bethesda, MD 20892–6200.

Contact Person: Helen R. Sunshine, Ph.D., Chief, Office of Scientific Review, NIGMS, 45 Center Drive, Room 1AS–13F, Bethesda, MD 20892–6200, 301–594–2881.

Purpose: To evaluate and review grant applications.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 193.821, Biophysics and Physiological Sciences; 93.859, Pharmacological Sciences; 93.862, Genetics Research; 93.863, Cellular and Molecular Basis of Disease Research; 93.880, Minority Access Research Careers [MARC]; and 93.375, Minority Biomedical Research Support [MBRS], National Institute of General Medical Sciences, National Institutes of Health)

Dated: October 30, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96–28631 Filed 11–6–96; 8:45 am]

BILLING CODE 4140–01–M

Prospective Grant of Exclusive License: Therapeutic Uses of Microtubule Stabilizing Agents Including Taxol (Paclitaxel) for Fibroproliferative Vascular Diseases Including Atherosclerosis and Restenosis and Excluding Cancer

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patents and patent applications referred to below to Angiotech Pharmaceuticals Inc. of Vancouver, British Columbia, Canada. The patent rights in these inventions have been assigned to the government of the United States of America. The patents and patent applications to be licensed are: ''Methods of Treating Atherosclerosis or Restenosis Using Microtubule Stabilizing Agent,'' U.S. Patent Application Serial No. 08/099,067 filed July 29, 1993; and all continuation applications, divisional applications, continuation-in-part applications, and foreign counterpart applications related to U.S. Patent Application Serial No. 08/099,067.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within ninety (90) days with the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

SUPPLEMENTARY INFORMATION: Atherosclerosis is the cause of the vast majority of cases of chronic peripheral arterial occlusive disease. The arteries most frequently involved, in order of occurrence, include femoropopliteal-tibial, aortioiliac, carotid and vertebral, splanchnic and renal, and brachycephalic. Fibromuscular dysplasia, inflammatory arteridities, and congenital arterial malformations are much rarer causes of arterial insufficiency. The process of repair after angioplasty continues over several months, involving re-endothelialization, proliferation of vascular smooth muscle cells, and remodelling of the extracellular matrix proteins. Restenosis, the natural regrowth of muscle cells, has been noted as the single greatest complication (30–50%) of interventional intravascular procedures which number approximately 500,000 procedure annually, and at $10,000 per procedure is costing the health care system approximately $5 billion annually. While both interventional and invasive treatments continue to improve, restenosis causes a first-time failure rate of up to 50% or more. Reduction in the restenosis rate for cardiovascular disease procedures is cited as the most critical factor in future improvements. If the rate could be reduced to 25%, it would represent a savings to the health care system of around $1 billion annually.

Preventing or reducing fibroproliferative vascular disease in a patient may be achieved by treating the patient with a pharmaceutical preparation comprising a therapeutically effective amount of a microtubule stabilizing chemotherapeutic agent such as taxol (placlitaxel). In particular, treatment with a low dose of a microtubule stabilizing agent such as taxol or a water-soluble taxol derivative may present or reduce atherosclerosis or restenosis after arterial injury. The low dose used prevents artery blockage while minimizing any negative side effects associated with the drug. Unlike classical anti-microtubule agents like colchicine and the vinca alkaloids which induce depolymerization of microtubules, taxol induces tubulin polymerization and forms extremely stable and nonfunctional microtubules.

ADDRESS: Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the contemplated license should be directed to: J. Peter Kim, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; Telephone: (301) 496–7056, ext. 264; Facsimile: (301) 402–0220. A signed Confidential Disclosure Agreement will be required to receive a copy of any pending patent application. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH on or before February 5, 1997 will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: October 29, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96–28633 Filed 11–6–96; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of Receipt of Applications for Permit

The following applicants have applied for a permit to conduct certain